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ORIGINAL ARTICLE
Multicenter Cohort Study, With a Nested 
Randomized Comparison, to Examine the 
Cardiovascular Impact of Preterm Preeclampsia
Fergus P. McCarthy , Jamie M. O’Driscoll , Paul T. Seed , Anna Placzek , Carolyn Gill , Jenie Sparkes ,  
Lucilla Poston, Mike Marber, Andrew H. Shennan, Basky Thilaganathan, Paul Leeson, Lucy C. Chappell
ABSTRACT: This study evaluated whether planned early delivery would ameliorate cardiovascular dysfunction 6 months 
postpartum, compared with usual care with expectant management, in women with late preterm preeclampsia. We conducted 
a mechanistic observational study in women with preterm preeclampsia between 34+0 and 36+6 weeks’ gestation, nested within 
a randomized controlled trial of planned early delivery versus expectant management (usual care), in 28 maternity hospitals in 
England and Wales. Women were followed up 6 months postpartum with cardiovascular assessments. The primary outcome 
was a composite of systolic and diastolic dysfunction (by 2009 and 2016 definitions of diastolic dysfunction). Between 
April 27, 2016, and November 30, 2018, 623 women were found to be eligible, of whom 420 (67%) were recruited. One 
hundred thirty-three women were randomized to planned delivery, 137 women were randomized to expectant management 
within the trial, while 150 women received expectant management outside of the trial. 321 (76.4%) completed their 6 month 
echocardiography assessment. 10% (31/321) had a left ventricular ejection fraction <55% while 71% (229/321) remained 
hypertensive. There were no differences in the primary outcome between the 2 randomized groups (planned delivery versus 
expectant management) using either the 2009 (risk ratio, 1.06 [95% CI, 0.80–1.40]) or 2016 definitions (risk ratio, 0.78 
[0.33–1.86]). In conclusion, we demonstrated that late preterm preeclampsia results in persistence of hypertension in the 
majority and systolic LV dysfunction in 10%, of women 6 months postpartum. Planned early delivery does not affect these 
outcomes. Preeclampsia is not a self-limiting disease of pregnancy alone. (Hypertension. 2021;78:00–00. DOI: 10.1161/
HYPERTENSIONAHA.121.17171.) • Data Supplement
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Preeclampsia affects 3% to 5% of pregnancies com-plicating ≈35 000 pregnancies in the United King-dom every year. Cardiovascular disease is the leading 
cause of mortality in women in the United Kingdom.1 
Hypertensive disorders of pregnancy, in particular preterm 
preeclampsia, have been shown to be associated with an 
increased risk of developing a wide range of cardiovas-
cular diseases, with increases in incidences observed as 
soon as one year postpartum.2 The absolute risk that a 
woman with preeclampsia would develop a cardiovascu-
lar event including hypertension, ischemic heart disease, 
stroke, or venous thromboembolism aged 50 to 59 is 
estimated to be 17.8% compared with 8.3% in those with-
out preeclampsia.3 The American Heart Association now 
recognizes preeclampsia as an independent risk factor 
for future cardiovascular disease.4 The economic burden 
of cardiovascular disease is substantial; the British Heart 
Foundation estimated that in 2006 cardiovascular disease 
cost the National Health Service in the UK £14.3 billion 
and the UK economy £30.6 billion,5 and the costs for EU 
health care systems related to cardiovascular disease is 
estimated at €110 billion, ≈10% of the total health care 
expenditure across the EU. With an increasingly ageing 
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To date, only case-control studies and small, single-
center cohort studies exist to provide evidence of associa-
tion between preeclampsia and persistent cardiovascular 
dysfunction. While some women have preexisting risk 
factors for preeclampsia that also predispose to cardio-
vascular disease, for whom preeclampsia may accelerate 
progression through adding a further stress, in others, 
preeclampsia occurs with no preexisting factors and may 
be the first hit in the pathway. There are several pos-
sible explanations for the additional cardiovascular insult 
from preeclampsia. These include subclinical myocardial 
injury, an increased susceptibility to undiagnosed chronic 
hypertension and subclinical atherosclerosis and dyslip-
idemia.6,7 This proposed research seeks to elucidate the 
role and extent of the myocardial stress in determining 
subsequent cardiac dysfunction.
We conducted a multicenter study of women with late 
preterm preeclampsia to evaluate the development of 
cardiovascular dysfunction at 6 months postpartum and 
to examine the cardiovascular effects of planned early 
delivery (compared with expectant management).
METHODS
Study Design and Participants
A woman was eligible for the study if she was between 34+0 
weeks and 36+6 weeks of gestation, had a diagnosis of pre-
eclampsia or superimposed preeclampsia (as defined by 
the International Society for the Study of Hypertension in 
Pregnancy),8 with a singleton or dichorionic diamniotic twin 
pregnancy and at least one viable fetus, was aged 18 years or 
older, and was able to give written informed consent. The only 
exclusion criterion to study participation was if a decision had 
already been made to deliver within the next 48 hours. There 
were no substantial changes to the published study design, 
methods, or outcomes after the start of the trial. The study 
was approved by the South Central—Hampshire B Research 
Ethics Committee (no. 13/SC/0645) and was nested within 
a larger trial of planned delivery versus expectant manage-
ment in women with late preterm preeclampsia (PHOENIX 
[Preeclampsia in Hospital: Early Induction or Expectant 
Management] trial; ISRCTN01879376). The data that support 
the findings of this study are available from the corresponding 
author upon reasonable request.
Procedures
Site research teams approached women to confirm eligibility 
and provided verbal and written information. A trained research 
midwife or clinician obtained written informed consent. A 
research team member entered baseline data on a web-based 
database. All other aspects of pregnancy management were 
expected to be in accordance with the UK national guidelines 
at the discretion of the responsible clinician.9 Usual care in the 
UK was expectant management until clinical concerns led to 
delivery or until 37 weeks’ gestation was reached. For those 
women participating in the trial, they were randomly assigned 
to planned delivery or expectant care in a 1:1 ratio as previ-
ously described.10 The allocation was not masked from women, 
clinicians, or data collectors due to the nature of the interven-
tion, but the study echocardiographer (J. O’Driscoll) remained 
masked to randomization group.
Outcomes were recorded on the web-based trial database 
through case-note review by trained researchers after maternal 
primary hospital discharge. Women were invited to return to their 
local hospital at least 6 months following delivery for echocar-
diography assessment, performed within an 8-week window of 
the 6-month timepoint. At this assessment, a brief medical his-
tory was recorded, blood pressure (BP) assessed, venepunc-
ture, and echocardiography undertaken. Echocardiography was 
performed locally according to a standard operating procedure 
circulated by the research team. Echocardiography discs with 
Nonstandard Abbreviations and Acronyms
BP blood pressure








• In women with late preterm preeclampsia there is per-
sistent hypertension in 70% and systolic dysfunction in 
10% at 6 months postpartum.
• The relatively short delay in those managed expectantly 
(compared with planned delivery) does not worsen car-
diovascular dysfunction at 6 months postpartum.
What Is Relevant?
• Routine delivery does not improve cardiovascular func-
tion, and when to deliver should depend on immediate 
maternal and fetal concerns.
Summary
Preeclampsia should not be considered a self-limiting 
disease of pregnancy alone and optimal screening 
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anonymized participant information were then sent to the lead 
echocardiographer (J. O’Driscoll) who analyzed each echocar-
diogram without knowledge of trial allocation, entering results 
onto the web-based trial database. Every tenth echo was sec-
ond read, again masked to trial allocation, by an echocardiog-
rapher at the University of Oxford and findings compared by 
the trial lead cardiologist (P. Leeson) to ensure consistency. 
When echocardiography assessment demonstrated potentially 
concerning features that may impact on clinical care, the find-
ings were escalated and reviewed by the lead cardiologist (P. 
Leeson) and communicated back to the lead clinician at the 
recruiting site with a recommendation for clinical follow-up.
Outcomes
The primary outcome was a composite of diastolic and systolic 
function at 6 months’ postpartum classified according to the joint 
recommendation by the American Society of Echocardiography 
and the European Association of Cardiovascular Imaging 
as assessed by transthoracic echocardiography with tissue 
Doppler studies classified originally in 200911 (at the time of 
study inception) and reclassified before study completion in 
2016.12 The primary outcome was chosen to reflect the sub-
clinical myocardial injury in preeclampsia. Additional secondary 
outcomes included the cardiovascular components of a mater-
nal morbidity composite outcome used in the main trial (severe 
hypertension post randomization; systolic BP ≥160 mm Hg on 
at least one occasion), positive inotropic support, infusion of 
a third parenteral antihypertensive drug, myocardial ischemia 
or infarction, SpO2 <90%, ≥50% FiO2 for >1 hour, intuba-
tion (other than for caesarean section), and pulmonary edema. 
The composite was chosen as an internationally accepted vali-
dated method for describing adverse maternal outcome from 
preeclampsia.13
Echocardiographic Assessment
All participants were studied by standard 2-dimensional and 
Doppler transthoracic echocardiography at rest. Women were 
studied in the left lateral decubitus position and data acquired 
at end expiration from standard parasternal/apical views using 
a GE Vivid or Philips scanner.11,14 For each acquisition, 3 cardiac 
cycles of noncompressed data were stored in cine-loop format 
and analyzed masked to group allocation by one investigator 
(J. O’Driscoll), with second read as described above. Cardiac 
indices were normalized for body surface area, height, and 
end-diastolic left ventricle (LV) long or short axis lengths, as 
appropriate.15–17 Tissue Doppler imaging, strain, and strain rate 
indices are given as absolute values.
Heart Remodeling
Chamber quantification and left ventricular geometric pat-
tern were estimated using M-mode as previously described.14 
Proximal septal bulging was assessed in the parasternal long-
axis and apical 4-chamber views.18
Systolic and Diastolic Dysfunction
Global LV diastolic function, estimated left heart filling pressures, 
and geometry was assessed and graded using standard diag-
nostic algorithms with the recommended adjustments reflect-
ing the concomitant systolic function and age.19 LV volumes and 
ejection fraction were derived from Simpson’s modified biplane 
method from apical 4-chamber and 2-chamber views, and LV 
systolic dysfunction was defined as ejection fraction <55%.14 
Hemodynamic and systolic cardiac indices were calculated as 
described before.20 Longitudinal and radial systolic function 
were assessed both globally and regionally using color and 
pulsed tissue Doppler velocity indices and strain rate indices 
using speckle tracking as previously described.21–25 Regional 
peak systolic strain rate index was considered abnormal if it 
was 2 SDs below the expected mean for age.26 This abnormal-
ity was defined as segmental myocardial impaired contractil-
ity. Regional diastolic dysfunction was defined as early to late 
strain rate ratio <1. This abnormality was defined as segmental 
impaired myocardial relaxation. Maternal BP was measured fol-
lowing the recommendations of the International Society for 
the Study of Hypertension in Pregnancy and National High 
Blood Pressure Education Programme Working Group on High 
Blood Pressure in Pregnancy.27
LV global systo-diastolic dysfunction was defined as LV 
global diastolic dysfunction in the presence of reduced ejec-
tion fraction (<55%). Right heart function and remodeling was 
assessed using integrating conventional echocardiographic 
indices and tissue Doppler velocity and deformation indices 
following published guidelines. The severity of left and right 
ventricle hypertrophy and dysfunction was graded accord-
ing to the European Association and American Society of 
Echocardiography guidelines11,14 with the following adjust-
ments described by Melchiorre et al27: age; increased circulat-
ing volume in pregnancy and the acute nature of preeclampsia 
on a previously normal cardiovascular system. For our primary 
outcome, diastolic dysfunction was classified as; normal; 
impaired myocardial relaxation with normal LV end diastolic 
pressure (GRADE I); pseudonormal filling pattern (GRADE II); 
and restrictive pattern (GRADE III) as previously described.23 
Findings were also reported according to American Society 
of Echocardiography/European Association of Cardiovascular 
Imaging 2016 guidelines, published after study conception and 
start of recruitment.28
Secondary outcomes included systolic BP and diastolic BP 
at 6 months postpartum, together with the cardiovascular com-
ponents of a composite maternal morbidity outcome adapted 
from the fullPIERS prediction of adverse events in preeclamp-
sia study.13,29
Myocardial Necrosis Assessment
Participants were also consented to at least 2 blood sampling 
time points, most commonly performed at initial recruitment 
and 6 month postpartum assessment. These samples were 
analyzed for markers of myocardial necrosis/ischemia: high 
sensitivity cTnI (cardiac troponins), with a sex specific level 
of >16 ng/L considered elevated.30 At 6 months postpar-
tum, cMyC (cardiac myosin binding protein C; using Singulex’s 
Single Molecule Counting Technology SMC a quantitative fluo-
rescent sandwich immunoassay technique) and NT-proBNP 
(N-terminal pro-B-type natriuretic peptide; Alere NT-proBNP 
for Alinity) were also assessed.
Statistical Analysis
Based on previous studies of postpartum echocardiography, 
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preterm preeclampsia having evidence of systolic and diastolic 
dysfunction at 6 months’ postpartum,23,31,32 a sample size of 
322 women were needed to detect a 25% relative risk reduc-
tion (from 70% to 52.5%; deemed clinically important) in the 
primary outcome in the planned delivery group compared with 
those managed expectantly with a 2 sided 5% significance 
level and 90% power. With 20% loss of women in follow-up 
the overall target for recruitment was 404 women. The primary 
analysis for all maternal outcomes was by intention to treat 
with participants analyzed in the groups to which they were 
assigned regardless of protocol noncompliances.
Risk ratios (RRs) were estimated for binary outcomes with 
associated 95% CIs. Simple and multiple regression analysis 
were used to assess the influence of early pregnancy factors 
including BP, demographic variables (maternal age, body mass 
index), pregnancy characteristics (parity, gestation at delivery, 
gestation at onset, and severity of preeclampsia), on indices of 
cardiac function and remodeling as detailed above under pro-
posed outcome measures. All of the conventional echocardio-
graphic indices were adjusted for body surface area14 and all of 
the tissue Doppler velocity and deformation indices to the end-
diastolic left or right ventricle long axis length.15 Prespecified 
subgroup analyses were performed for co-primary outcomes in 
view of changes to definitions of systolic and diastolic dysfunc-
tion over the study period. Data analyses and power calcula-
tions were performed using STATA/SE version 15.1.
RESULTS
Participants
Between April 27, 2016, and November 30, 2018, 623 
women were found to be eligible, of whom 420 (67%) 
were recruited, across 28 maternity units in England and 
Wales. Of these 420, 133 women were randomly allo-
cated to planned delivery, 137 women were randomly 
allocated to expectant management, and 150 received 
usual care and were managed expectantly as indicated 
by national guidelines (Figure). In total, 99 (23.6%) of 
women did not attend their 6-month echocardiogra-
phy appointment; 321 women (76.4%) completed their 
6-month follow-up and had cardiac echocardiogra-
phy. For the intention-to-treat analysis, data from 100 
women in the planned delivery group and 107 women 
in the expectant management group were included. Fol-
low-up to 6 months postpartum assessments continued 
until 20 June 2019. Baseline characteristics appeared 
similar between the 2 groups, with groups well balanced 
on minimization factors (Table 1). Women who did not 
attend their 6-month follow-up (n=99) were similar in 
baseline characteristics compared with women who 
completed their 6-month follow-up (Tables S1 and S2 in 
the Data Supplement).
Outcome Data
Of the 321 women within the cohort, 51% (n=164) and 
10% (n=31) had the primary outcome using 2009 and 
2016 definitions, respectively. Overall, 10% (31/321) of 
women had an LVEF <55% 6 months postpartum. Using 
2009 diastolic dysfunction sub-classification, 9% (n=27) 
of women had grade I, 40% (n=123) grade II and 1% 
(n=3) grade III dysfunction. Using the newer 2016 dia-
stolic sub-classification, 18% (n=58), 2% (n=5), and 0% 
(n=1) had 1, 2, and 3 diastolic dysfunction criteria present, 
respectively (Table 3). Hypertension prevalence, defined 
as on antihypertensive treatment or systolic BP >140 
mm Hg ±diastolic BP >90 mm Hg 6 months postpartum 
was present in 71% (n=229) of the cohort. Seventeen 
percent (n=50) of women had evidence of concentric 
remodeling and 1% (n=3) had evidence of eccentric 
remodeling. At 6 months postpartum, 1% (n=4) of women 
had a high sensitivity cTnI >16 ng/L, 13.2% (n=38) NT-
proBNP >100 ng/L, and 0.7 (n=2) had a MyC >87ng/L.
Nested Randomized Comparison
There were no differences between women in the 
planned delivery group compared with the expectant 
management group in the primary outcome using either 
the 2009 (RR, 1.06 [0.80–1.40]) or 2016 definitions 
(RR, 0.78 [0.33–1.86]) shown in Table 3. No between 
group differences were observed in 2009 diastolic dys-
function grade 1 (RR, 1.40 [0.59–3.31]), grade 2 (1.11 
[0.78–1.57]), or grade 3 (1.18 [0.08–18.43]) diastolic 
dysfunction sub-classification nor in 2016 diastolic 
dysfunction classification. Using the more recent 2016 
classification for systolic and diastolic dysfunction, simi-
larly no differences were observed in systolic (RR, 0.76 
[0.32–1.80]) or any of the diastolic dysfunction parame-
ters. Hypertension prevalence 6 months postpartum was 
similar between those managed with planned delivery 
compared with those expectantly managed (RR, 1.01 
[0.85–1.20]). No significant differences were observed 
in any of the cardiac parameters including geometric 
and hemodynamic parameters, LV global cardiac param-
eters, myocardial mechanics, and LV basal or apical 
parameters between those women with planned deliv-
ery compared with those expectantly managed (Table 3 
and Table S3). The high prevalence of systolic and dia-
stolic dysfunction or persistent hypertension was not 
explained by preexisting chronic hypertension as when 
these women were excluded (n=37, 11%), systolic and 
diastolic dysfunction was evident in 49.5% and hyper-
tension in 68.7% of women.
Mean time from enrolment to delivery was 2.5 (SD 
1.9) days in the planned delivery group compared with 
6.8 (5.3) days in the expectant management group. No 
differences were observed between groups in cardiore-
spiratory outcomes before discharge from hospital nor 
in any systolic or diastolic BP measurements (Table 4).
Within the entire cohort (n=321), the only variables 
affecting development of systolic and diastolic dysfunc-
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body mass index (adjusted odds ratio, 1.33 [1.12–1.59] 
per 5 kg/m2) and maternal age (2.16 [1.44–3.22] per 
10 years; Table 5). Interval from study enrolment to deliv-
ery was not associated with development of the primary 
outcome. There were no significant predictor variables 
for systolic and diastolic dysfunction 6 months postpar-
tum by the updated 2016 definition (Table 5). Inclusion 
of antenatal high sensitivity cTnI did not alter the results.
Overall, 8% (n=25) women had their clinical echocar-
diograms escalated by the trial cardiologist with clinical 
follow-up recommended. These were for a combination 
of structural (n=8), valvular (n=8), functional (n=9), or 
combined (n=2) findings. These clinical escalations 
accounted for 12% of those with the primary outcome 
(2009 definition), with 88% of those with systolic and 
diastolic dysfunction not requiring clinically escalation.
DISCUSSION
This large multicenter study highlights the substantial 
adverse cardiovascular sequelae of preterm preeclamp-
sia; 10% of women with preterm preeclampsia had a 
LVEF <55%, 71% remained hypertensive, and 49% of 
women had evidence of impaired diastolic dysfunction 
of undetermined long-term clinical importance 6 months 
postpartum. In the nested randomized controlled trial of 
women with late preterm preeclampsia, planned deliv-
ery did not reduce cardiovascular dysfunction 6 months 
postpartum. Women in the planned delivery group had a 
mean shortening of pregnancy from enrolment to deliv-
ery of 4 days, but this did not result in decreased hyper-
tension or cardiovascular dysfunction compared with 
those managed with usual care by expectant manage-
ment. Only elevated body mass index and higher age at 
enrolment predicted the occurrence of postpartum sys-
tolic and diastolic dysfunction. The short time to delivery 
in the expectant arm may not have resulted in sufficient 
time for any longer term cardiovascular insult to be exac-
erbated, explaining why earlier delivery does not benefit 
the mother in this outcome.
This large, multicenter trial represents UK contem-
poraneous management of women with late preterm 
preeclampsia, subsequently followed up by detailed 
standardized BP and echocardiography assessment 
6 months postpartum. Our cohort sample size (321 
women) is considerably larger than any other postpar-
tum cardiovascular study previously performed. We are 
unaware of any published randomized controlled trials 
evaluating the impact of timing of delivery on subsequent 
maternal cardiovascular function. The randomized design 
allowed us a unique opportunity to explore the impact 
of earlier delivery on postpartum cardiovascular function.
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Strengths of this study include a sufficiently large 
sample of women with late preterm preeclampsia from 
28 centers throughout the UK completing a detailed 
6-month postpartum cardiovascular assessment to 
describe the burden of cardiovascular disease in this 
population, linking preeclampsia with longer term car-
diovascular disease. The trial was conducted to rigorous 
standards, with a prespecified protocol without changes. 
Findings are likely to be generalizable to similar health 
care settings, because it was undertaken in a large 
number of maternity units across England and Wales, 
with diverse representation of women in terms of both 
demography and disease spectrum. More than half of 
eligible women approached agreed to participate in the 
trial, indicating agreement of equipoise in this scenario. 
Echocardiograms were performed by multiple echocar-
diographers throughout the UK and Wales, representa-
tive of cardiology units throughout the National Health 
Service. We have reported all prespecified secondary 
outcomes, interpreting them cautiously.
Limitations of the trial include a change in the inter-
national definition regarding systolic and diastolic dys-
function, such that interpretation of the findings need 
to be undertaken in the light of the prespecified 2009 
definition11 and the later 2016 definition.12 Our results 
reflect systolic and diastolic definitions used first in 
2009 and then updated in 2016. We acknowledge that 
there is an interim group with a LVEF between 50% and 
55% and further prospective follow-up would help our 
understanding of the implications of this impairment in 
Table 1. Baseline Maternal Demographic and Pregnancy Characteristics at Trial Entry on All Women Who 
Had 6 Month Echocardiography (n=321)
Maternal demographic and preg-
nancy characteristics









ment (usual care non-
randomized; n=114)
 N (%) N (%) N (%) N (%)
Age at randomization, y mean (SD) 31.59 (5.87) 30.56 (6.11) 31.26 (6.14) 32.81 (5.18)
Ethnicity
 White 229 (71.3) 76 (76.0) 83 (77.6) 70 (61.4)
 Asian 34 (10.6) 13 (13.0) 10 (9.3) 19 (16.7)
 Black 42 (13.1) 8 (8.0) 6 (5.6) 20 (17.5)
 Mixed 10 (3.1) 2 (2.0) 6 (5.6) 2 (1.8)
 Other 6 (1.9) 1 (1.0) 2 (1.9) 3 (2.6)
Deprivation index quintile
 1 (Least deprived) 24 (7.5) 12 (12.0) 7 (6.5) 5 (4.4)
 2 51 (15.9) 13 (13.0) 20 (18.7) 18 (15.8)
 3 46 (14.3) 14 (14.0) 13 (12.1) 19 (16.7)
 4 77 (24.0) 23 (23.0) 28 (26.2) 26 (22.8)
 5 (Most deprived) 123 (38.3) 38 (38.0) 39 (36.4) 46 (40.4)
Parity (previous pregnancies ≥24 wk gestation)*
 0 207 (64.5) 64 (64.0) 68 (64) 75 (66)
 1 69 (21.5) 24 (24.0) 19 (18) 26 (23)
 2 22 (6.9) 4 (4.0) 11 (10) 7 (6)
 >2 23 (7.2) 8 (8.0) 9 (8) 6 (5)
Previous caesarean section* 52 (16) 13 (13) 19 (18) 20 (34)
History of preeclampsia 51 (16) 15 (15) 17 16) 19 (17)
BMI at booking, kg/m2
 Mean (SD) 30.2 (7.5) 30.2 (9.0) 30.0 (7.4) 30.3 (6.2)
Smoking status at booking
 Never smoked 257 (80) 81 (81) 79 (73.8) 97 (85.1)
 Quit before booking 47 (14.6) 14 (14) 22 (20.6) 11 (9.6)
 Smoking at booking 17 (5.3) 5 (5.0) 6 (5.6) 6 (5.3)
Blood pressure 48 h before enrolment, mm Hg
 Systolic (mean, SD) 153 (15) 153 (15) 155 (15) 154 (15)
 Diastolic (mean, SD) 95 (10) 96 (10) 96 (11) 94 (9)
BMI indicates body mass index.
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Table 2. Maternal Clinical Characteristics for Women With Primary Outcome
Maternal clinical characteristics









ment (usual care non-
randomized; n=114)
Gestational age at enrolment*, wk
 Median (IQR) 35.6 (34.9–36.1) 35.6 (34.9–36.2) 35.6 (34.7–36.1) 34.4 (34.4–34.4)
  34+0 to 34+6 106 (33.0) 28 (28.0) 32 (29.9) 46 (40.4)
  35+0 to 35+6 107 (33.3) 34 (34.0) 38 (35.5) 35 (30.7)
  36+0 to 36+6 108 (33.6) 38 (38.0) 37 (34.6) 33 (28.9)
Pregnancy type
  Singleton 296 (92.2) 90 (90.0) 96 (89.7) 110 (96)
  Twin 25 (7.8) 10 (10.0) 11 (10.3) 4 (4)
Comorbidity at study entry (nonexclusive)
 Preexisting chronic hypertension 37 (11.5) 11 (11.0) 13 (12.1) 13 (11.4)
 Preexisting chronic renal disease 3 (0.9) 2 (2.0) 1 (0.9) 0 (0.0)
 Prepregnancy diabetes 18 (5.6) 6 (6.0) 3 (2.8) 9 (7.9)
 Gestational diabetes 40 (12.5) 14 (14.0) 12 (11.2) 14 (12.3)
Severity of hypertension in 48 h before enrolment, mm Hg†
 Systolic BP mean (SD) 153 (14) 153 (14) 155 (15) 154 (15)
 Diastolic BP mean (SD) 95 (10) 96 (10) 96 (10) 94 (9)
 ≤149 mm Hg (n, %) 124 (38.6) 41 (41.0) 38 (35.5) 45 (39.5)
 150–159 mm Hg (n, %) 91 (28.3) 28 (28.0) 34 (31.8) 29 (25.4)
 ≥160 mm Hg (n, %) 106 (33.0) 31 (31.0) 35 (32.7) 40 (35.1)
Oral antihypertensive medications at study entry
 0 agents 53 (16.5) 21 (21.0) 15 (14.0) 17 (14.9)
 1 agent 171 (53.3) 53 (53.0) 59 (55.1) 59 (51.8)
 ≥2 agents 97 (30.2) 26 26.0) 33 (30.8) 38 (33.3)
Aspirin prescribed during pregnancy 138 (43) 47 (47.0) 42 (39.3) 49 (43.0)
LMWH prescribed at enrolment‡ 114 (35.5) 32 (32.0) 38 (35.5) 44 (38.6)
Most recent lab parameters before study entry (mean; SD)
Protein-creatinine ratio, mg/mol 158 (260) 137 (160) 210 (389) 128 (151)
Hemoglobin, g/L 116 (12) 117 (11) 117 (12) 115 (12)
Platelets, ×109/L 217 (75) 228 (101) 207 (52) 217 (65)
Creatinine, µmol/L 61 (14) 58 (14) 61 (12) 63 (15)
Alanine aminotransferase, U/L 26 (36) 25 (28) 22 (34) 30 (43)
Aspartate aminotransferase, U/L 54 (151) 125 (295) 20 (9) 22 (18,31)
Suspected fetal growth restriction 63 (22.6) 22 (27.8) 20 (20.4) 21 (20.6)
Antenatal ultrasound findings
 AC <10th 14 (5.0) 5 (6.3) 4 (4.1) 5 (6.3)
 EFW <10th 54 (19.4) 18 (22.8) 19 (19.4) 17 (16.7)
 Umbilical artery PI >95th 9 (3.2) 5 (6.3) 1 (1.0) 3 (2.9)
 AREDF 2 (0.7) 0 (0.0) 0 (0.0) 2 (2.0)
 AFI <5th 5 (1.8) 2 (2.5) 1 (1.0) 2 (2.0)
In-patient at time of trial entry
 Yes 262 (81.6) 75 (75.0) 90 (84.1) 97 (85.1)
Biomarkers at enrolment
High sensitivity cardiac troponin I median (IQR), ng/L 5 (5–6) 5 (5–5) 5 (5–6) 5 (5–6)
>16 ng/L 12 (3.9) 2 (2.1) 5 (4.9) 5 (4.5)
AC indicates abdominal circumference; AFI, amniotic fluid index; AREDF; absent or reverse end diastolic flow; BP, blood pressure; EFW, estimated fetal weight; IQR, 
interquartile range; LMWH, low molecular weight heparin; and PI, pulsatility index.
*Minimization factors used to ensure balance at randomization.
†These are summary statistics for the mean of an individual’s 2 BP readings.
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women following pregnancy. We prespecified use of 
the independent definition of systolic and diastolic dys-
function for this particular patient group as defined by 
Melchiorre et al, adapted from recommendations of the 
American Society of Echocardiography/European Asso-
ciation of Cardiovascular Imaging11 with adjustments for 
age, the higher circulating volume in pregnancy and the 
acute nature of preeclampsia in an otherwise previously 
normal cardiovascular system.23 Newer nonpregnant 
specific definitions (American Society of Echocardiog-
raphy/European Association of Cardiovascular Imaging 
guidelines 2016)28 result in lower prevalence of diastolic 
dysfunction but cardiovascular morbidity is still evident 
and prevalent. There was a relatively short difference of 
a median 4 days in those managed with planned deliv-
ery compared with women managed expectantly, and it is 
Table 3. Primary and Secondary Outcomes at 6 Months Postpartum
Primary and secondary outcomes
















 (%) (%) (%) Risk ratio  
Primary outcome (2009 definition)
 Diastolic and systolic dysfunction postpartum 164 (51) 50/100 (50.0) 50/106 (47.2) 1.06 (0.80–1.40) 64 (56.1)
  Systolic dysfunction (yes/no) defined as left ven-
tricular ejection fraction <55%
31 (10) 8/98 (8.2) 11/102 (10.8) 0.76 (0.32–1.80) 12 (10.8)
 Diastolic dysfunction sub-classification†  n=96 n=103   
Normal 157 (51) 48 (50.0) 57 (55.3)  52 (46.8)
Impaired myocardial relaxation with normal left ven-
tricular end diastolic pressure (GRADE I)
27 (9) 10 (10.4) 8 (7.8) 1.40 (0.59–3.31) 9 (8.1)
Pseudonormal filling pattern (GRADE II) 123 (40) 37 (38.5) 37 (35.9) 1.11 (0.78–1.57) 49 (44.1)
Restrictive pattern (GRADE III) 3 (1) 1 (1.0) 1 (1.0) 1.18 (0.08 to 18.43) 1 (0.9)
Primary outcome (2016 definition)
Diastolic and systolic dysfunction postpartum 31 (10) 8/100 (8.2) 11/107 (10.3) 0.78 (0.33 to 1.86) 12 (10.5)
Systolic dysfunction (yes/no) defined as LVEF <55% 31 (10) 8/98 (8.2) 11/102 (10.8) 0.76 (0.32 to 1.80) 12 (10.8)
Diastolic dysfunction (yes/no; >50%/≥3–4 positive) 5 (2) 1/100 (1.0) 0/107 (0.0) NA 0 (0.0)
Average E/e′ >14 1 (1.0) 1/96 (1.0) 2/99 (2.0) 0.52 (0.05 to 5.59) 0 (0.0)
Septal e′ velocity <7 cm/s or Lateral e′ velocity <10 
cm/s
45 (14.0) 15/96 (15.6) 13/103 (12.6) 1.24 (0.62 to 2.46) 17 (15.0)
Tricuspid regurgitant velocity >2.8 m/s 3 (0.9) 1/100 (1.0) 0/107 (0) … 2 (1.8)
Left atrial volume index (>34 mL/m2) 13 (4.0) 4/98 (4.1) 3/106 (2.8) 1.44 (0.33 to 6.28) 6 (5.4)
Diastolic dysfunction criteria present  n=100 n=107   
0 257 (80.0) 82 (82.0) 90 (84.1)  89 (78.1)
1+ 58 (18.0) 16 (16.0) 16 (15.0) … 23 (20.2)
2+ 5 (2.0) 1 (1.0) 1 (0.9) … 2 (1.8)
≥3+ 1 (0) 1 (1.0) 0 (0.0) … 0 (0.0)
Secondary outcomes
Hemodynamic  n=100 n=107   
Systolic blood pressure 123 (16) 124 (14) 123 (17) 1.48 (−2.88 to 5.85) 124 (15)
Diastolic blood pressure 76 (13) 76 (13) 75 (13) −0.59 (−2.96 to 4.14) 76 (13)
Hypertension prevalence (on antihypertensive 
treatment±or systolic BP >140 ±diastolic BP >90
229 (71) 72 (72) 76 (71) 1.01 (0.85 to 1.20) 81 (71)
Biomarkers at 6 mo follow-up  n=92 n=100   
High sensitivity cTnI >16 ng/L 4 (1.4) 1 (1) 1 (1) 1.09 (0.07 to 17.13) 2 (2.0)
NT-proBNP >100 ng/L 38 (13.2) 10 (11) 15 (15) 0.72 (0.34 to 1.52) 13 (13.1)
MyC >87 ng/L 2 (0.7) 1 (1) 1 (1) 1.10 (0.07 to 17.31) 0 (0.0)
As not every echocardiography parameter was available on each examination, individual denominators are shown where applicable. E/A: <0.73; 0.73–2.33; >2.33; DT: 
>194 ms; 138–194 ms; <138 ms; and IVRT; >83 ms; 51–83 ms; <51 ms. E/e′ indicates ratio of the peak early mitral inflow velocity (E) over the early diastolic mitral 
annular velocity (e′); and NT-proBNP, N-terminal pro-B-type natriuretic peptide.
*Effect measure adjusted for gestational age at study entry.
†Graded I–III using the median value from the classification of the variables E/A (early to late diastole peak transmitral velocity ratio), deceleration time (DT) of E wave 
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likely that this difference may not have been sufficiently 
long to result in detectable differences in cardiovascular 
function 6 months postpartum. Approximately, one-third 
of the women recruited for this study had been eligible for, 
but declined participation in the main PHOENIX trial, and 
as a result were included as a nonrandomized expect-
ant management (usual care) group. Results across all 
groups were very similar. We did not recruit women with 
a healthy pregnancy, as our primary research question 
was whether shortening of pregnancy after diagnosis of 
preterm preeclampsia altered the prevalence of cardio-
vascular dysfunction 6 months postpartum.
We considered sources of possible bias for our trial. 
Selection bias into the trial was unlikely due to the 
randomization process, which included robust alloca-
tion sequence concealment such that determining next 
allocation was not possible. Performance and detection 
bias were possible because it was not possible to mask 
participating clinicians or women, nor data collectors 
because timing of delivery was contained within maternity 
records where morbidity was recorded. However, the trial 
echocardiographer was masked to randomization groups 
and each echocardiogram was, therefore, read indepen-
dent of knowledge of trial allocation. There was expected 
attrition to 6 month follow-up of around 20% in both 
groups, but data completeness of pregnancy outcomes 
was high (over 99%). The study was originally powered 
for an analysis of 322 women comprised of 161 women 
in 2 treatment groups. However, it became apparent 
that a group of eligible women chose not to consent to 
the main randomized comparison in the PHOENIX trial 
but would consent for the observational PHOEBE (also 
known as PHOENIX-3) study, with all women in this 
group following usual care, which was expectant man-
agement. The aims of the PHOEBE study were primar-
ily to explore the mechanism behind the effect of the 
intervention (earlier timing of delivery) and to provide an 
understanding of postpartum cardiovascular dysfunction 
after preterm preeclampsia. We acknowledge that we 
were underpowered for examining the effect of the inter-
vention. The primary outcome event rate was also lower 
than expected by both 2009 and 2016 guidelines. For the 















Cardiorespiratory outcomes before discharge from hospital
 Positive inotropic support 0 (0.0) 0 (0.0) 0 (0.0) … 0 (0.0)
  Infusion of a third parenteral antihyperten-
sive drug
1 (0.3) 0 (0.0) 0 (0.0) … 1 (0.9)
 Myocardial ischemia or infarction 1 (0.3) 1 (1.0) 0 (0.0) … 0 (0.0)
 SpO2 <90% 1 (0.3) 1 (1.0) 0 (0.0) … 0 (0.0)
 ≥50% FiO2 for >1 h 0 (0.0) 0 (0.0) 0 (0.0) … 0 (0.0)
 Intubation (other than for caesarean section) 0 (0.0) 0 (0.0) 0 (0.0) … 0 (0.0)
 Pulmonary edema 0 (0.0) 0 (0.0) 0 (0.0) … 0 (0.0)
 Time from enrolment to delivery (mean; SD) 5.7 (5.0) 2.5 (1.9) 6.8 (5.3) MD, −3.83 (−5.61 to −2.06) 7.6 (5.3)
 Gestational age at delivery, wk 36.2 (1.0) 35.9 (0.8) 36.4 (1.0) MD, −0.55 (−0.80 to −0.29) 36.4 (1.1)
  Highest Systolic BP enrolment to delivery 
(mean; SD)
162 (16) 156 (17) 164 (15) MD, −8.06 (−12.47 to −3.65) 164 (15)
  Highest diastolic BP enrolment to delivery 
(mean; SD)
96 (11) 94 (10) 97 (13) MD, −3.16 (−6.27 to −0.04) 98 (10)
  Highest systolic BP delivery to hospital dis-
charge (mean; SD)
156 (16) 154 (15) 157 (17) MD, −3.58 (−7.99 to 0.83) 157 (16)
  Highest diastolic BP delivery to hospital 
discharge (mean; SD)
92 (13) 90 (13) 93 (14) MD, −3.09 (−6.84 to 0.66) 93 (12)
 Birth centile* (median, IQR) 23.8 (8.3,54.3) 29.7 (10.0, 58.0) 17.4 (8.3, 50.6) MedD, 6.34 (−0.98 to 13.67) 23.7 (5.6, 57.2)
 Birth centile <10th centile 105 (30.3) 27 (24.5) 35 (29.7) RR, 0.83 (0.54 to 1.27) 43 (36.4)
 Birth centile <third centile 31 (9) 7 (6.4) 9 (7.6) RR, 0.83 (0.32−2.16) 15 (12.7)
BMI 6 mo follow-up (n, %)
 Normal 66 (21) 22 (22) 26 (24) NA 18 (16)
 Overweight 94 (29) 30 (30) 31 (29)  33 (29)
 Obese 160 (50) 48 (48) 50 (47)  62 (55)
 Breast feeding at 6 mo follow-up (yes; n, %) 81 (25) 21 (21) 19 (18) N/A 41 (36)
BMI indicates body mass index; MD, mean difference; MedD, median difference; and RR, risk ratio.
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evaluation of the effect of the intervention, the 2 random-
ized groups were compared (as described in the Statisti-
cal Analysis Plan). As there was no signal of a significant 
effect in the secondary outcomes, it would suggest that 
we had not missed an important difference in the primary 
outcome (likely to be related to the much shorter sepa-
ration in time between randomization and initiation of 
delivery between the 2 groups than anticipated). In light 
of this, we also combined all women recruited to provide 
an overall cohort of 321 women in which to complete 
the prognostic assessment (presented in Table 5) and to 
present a detailed cardiovascular assessment on a large 
prospective cohort of women with preterm preeclampsia. 
We chose 6 months as a generally accepted timepoint 
that pregnancy changes have resolved and underly-
ing cardiovascular changes could not be attributed to 
pregnancy alone. This figure was also based on others’ 
work showing that persistent cardiovascular changes 
are present as early as 6 months postpartum.23 Maternal 
and neonatal outcomes before discharge from hospital 
between those randomized to immediate or expectant 
management are presented in Table S4 and do not dif-
fer significantly. In our original cohort, 12% had preexist-
ing chronic hypertension. At the 6 month follow-up, 71% 
of women were classified as having chronic hyperten-
sion not explained by other factors other than exposure 
to preterm preeclampsia. 241 (75%) of women were 
not breast feeding and 81 (25%) of women continued 
to breast-feed (including as part of mixed feeding) at 6 
months postpartum. Exploratory analysis demonstrated 
that our primary outcome was unaffected by breast-
feeding status (odds ratio, 1.20 [0.78–1.87]; P=0.43). 
At the 6 month follow-up, 79% of women were classi-
fied as overweight or obese, but hypertension was seen 
across all weight groups. The occurrence of chronic 
hypertension at 6 months was not dependent on the 
body mass index category. The occurrence of chronic 
hypertension at 6 months was not dependent on the 
body mass index category. The proportion of women 
with chronic hypertension 6 months postpartum was 
similar across the 3 main weight categories as follows; 
normal weight 71% (47/66); overweight 60% (57/94); 
and obese 57% (91/160).
A recent systematic review summarized 36 studies of 
maternal cardiovascular function involving 815 women 
at time of disease with preeclampsia, demonstrated that 
increased vascular resistance and LV mass were the 
most consistent findings in preeclampsia.33 Differentiat-
ing features of a pregnancy complicated by preeclamp-
sia from normal pregnancy include LV wall thickness of 
≥1.0 cm, exaggerated reduction in early diastole/atrial 
contraction, and lateral e′ of <14 cm/s, markers of dia-
stolic dysfunction. Reduced stroke volume, diastolic dys-
function, and LV remodeling are most marked in severe 
Table 5. Effect of Baseline Characteristics on the Development of Cardiovascular Dysfunction (2009 and 
2016 Definition) at 6 Months Postpartum (All 321 Women)
Maternal baseline characteristics
2009 Definition 2009 Definition 2016 Definition
Unadjusted odds ratios 
(95% CI)
Adjusted odds ratios 
(95% CI)**
Unadjusted odds ratios 
(95% CI)
At enrolment variables
Systolic blood pressure (per 10 mm Hg) 1.000 (0.999–1.002) 1.000 (0.998–1.002) 0.999 (0.996–1.001)
Diastolic blood pressure (per 10 mm Hg) 1.001 (0.998–1.003) 1.001 (0.999–1.003) 0.999 (0.996–1.003)
Height (per 10 cm) 1.042 (0.768–1.414) 1.010 (0.736–1.386) 1.157 (0.688–1.949)
Weight (per 1 kg) 1.016 (1.004–1.027) 1.000 (0.969–1.031) 1.005 (0.988–1.023)
BMI (per 5 kg/m2) 1.294 (1.091–1.534) 1.334 (1.118–1.592)† 1.058 (0.815–1.373)
Age (per 10 y) 2.034 (1.375–3.008) 2.156 (1.444–3.217)† 1.161 (0.621–2.172)
Smoking status: current 1.797 (0.648–4.983) 1.773 (0.624–5.037) 1.310 (0.284–6.054)
CTnI at enrolment, >16 ng/L 0.993 (0.313–3.150) 1.044 (0.322–3.380) 1.8 (0.203–15.921)
Post enrolment variables
Time from study recruitment to delivery 0.873 (0.636–1.197) 0.986 (0.709–1.373) 0.958 (0.567–1.617)
Highest systolic blood pressure enrolment to 
delivery (per 10 mm Hg)
1.000 (0.999–1.002) 1.000 (0.999–1.002) 0.999 (0.997–1.001)
Highest diastolic blood pressure enrolment to 
delivery (per 10 mm Hg)
1.001 (0.999–1.003) 1.001 (0.999–1.003) 1.002 (0.998–1.005)
Adverse maternal event (dichotomous)* 1.148 (0.701–1.881) 1.155 (0.688–1.940) 0.677 (0.310–1.480)
Gestational age at delivery 0.993 (0.963–1.024) 0.990 (0.958–1.023) 1.018 (0.705–1.471)
BMI indicates body mass index; and CTnI, cardiac troponin.
*Adverse maternal event is defined using the PHOENIX study protocol as a composite of maternal morbidity adapted from the fullPIERS 
model for prediction of preeclampsia adverse events (von Dadelszen et al, Lancet 2011) which will include central nervous system, cardio-
respiratory, hematological, hepatic, and renal outcomes together with placental abruption, intensive care unit admission as well as confirmed 




 http://ahajournals.org by on Septem
ber 1, 2021
ORIGINAL ARTICLE
McCarthy et al Preterm Preeclampsia and Cardiovascular Dysfunction
Hypertension. 2021;78:00–00. DOI: 10.1161/HYPERTENSIONAHA.121.17171 October 2021  11
and early-onset preeclampsia.23,31,34 Our finding of car-
diovascular dysfunction and persistent hypertension in 
the majority of women following preterm preeclampsia 
is in keeping with other single-center observational stud-
ies.35–44 However, none were multicenter nor designed to 
examine different maternal delivery strategies. Our find-
ing of 71% of women with preterm preeclampsia remain-
ing hypertensive 6 months postpartum is higher than 
reported in larger population based cohorts, highlighting 
high levels of presumed undiagnosed hypertension.45 As 
the PHOENIX trial has now reported, it is unlikely that 
the opportunity will arise for other investigators to exam-
ine whether timing of delivery impacts cardiovascular 
function using such a randomized approach. Developing 
accurate validated prognostic tools to best identify those 
at highest risk of cardiovascular dysfunction remains 
challenging, and postpartum intervention strategies must 
now be explored to reduce this cardiovascular burden of 
disease.
We have demonstrated that the burden of postpartum 
cardiovascular dysfunction following preterm preeclamp-
sia in these women is high. In low resource health care 
settings where under-detected comorbidities including 
chronic hypertension are high and cases of fulminant 
eclampsia prevalent (incidence 1.4%),46 the burden of 
cardiovascular morbidity is likely much higher. Recent 
US data suggest stagnation in the improvements in 
incidence and mortality of cardiovascular disease, spe-
cifically among younger women.47 It is imperative that we 
understand the mechanisms that contribute to worsen-
ing risk factor profiles in young women to reduce future 
cardiovascular morbidity and mortality.
Two decades of research have documented an asso-
ciation between preeclampsia and major cardiovas-
cular disorders in later life.2,3,48,49 Despite this body of 
evidence, usual practice after a pregnancy complicated 
by preterm preeclampsia is for no specific follow-up. It 
is recognized by the Joint British Societies that include 
the British Cardiac Society, Heart UK, and the British 
Hypertension Society that pregnancy and infancy are 
good opportunities for education and intervention.50 Fur-
thermore, they endorse intensive risk factor lowering in 
individuals with high-risk factors that cause cardiovas-
cular disease. Women with preterm preeclampsia are 
at increased risk for cardiovascular disease later in life. 
This study has provided mechanistic information on how 
subsequent clinical cardiovascular events may be medi-
ated through impaired cardiac function identifiable at 6 
months after preterm preeclampsia and highlights the 
postpartum period as an opportunity for early interven-
tion before sustained and irreversible damage. There is 
increasing interest in the role of lifestyle interventions 
and therapeutic (eg, with angiotensin-converting enzyme 
inhibitors) to reduce subsequent cardiovascular risk. This 
study provides a body of evidence for postpartum car-
diac functional impairment and demonstrates the need 
for further research into early intervention, particularly 
relating to novel therapeutic pathways.
PERSPECTIVES
In conclusion, our study confirms that late preterm pre-
eclampsia is associated with substantial postpartum 
cardiovascular dysfunction. The relatively short delay 
in those expectantly managed (compared with planned 
delivery) does not worsen this cardiovascular dysfunc-
tion. Further follow-up would be useful to understand the 
longer term cardiovascular implications of these findings 
and whether these parameters relate to hypertension, 
age, or increased body mass index. Preeclampsia should 
not be considered a self-limiting disease of pregnancy 
alone. This research improves our understanding of the 
mechanistic processes linking preeclampsia with mater-
nal cardiovascular impairment. Earlier delivery does not 
improve or worsen postpartum cardiovascular dysfunc-
tion, and women can be reassured that prolongation of 
a pregnancy affected by preterm preeclampsia will not 
further worsen their cardiovascular health. The study 
informs counseling of women with preeclampsia around 
future risks and also identifies the postpartum period now 
as a critical area to target in future intervention studies.
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